There was also a significant decrease in leukemia burden as assessed by percent human (h) CD19+ cells within the peripheral blood and spleen in the combination treated group versus dasatinib alone (Figure 1B), which are concordant with our recent study testing various PI3K pathway inhibitors in other Ph-like B-ALL xenografts [13]. Here, CD19 is linked to acute lymphoblastic leukemia.